Finnish company Medicortex Finland Oy has started trials on its diagnostic kit – which it is hoped will improve the tools available in the detection of brain injuries that show no symptoms.

The trials will take place at Satasairaala hospital in Finland in the coming months – coronavirus permitting.

Dr. Mårten Kvist, medical director of Medicortex Finland Oy, said: “A diagnostic kit for rapid detection of mild TBI in children is truly important. It will satisfy the urgent need to improve the detection of brain injury in children who suffered a head injury”

The rapid diagnostic kit ProbTBI helps to diagnose brain injury especially in patients who don’t show visible symptoms of brain damage – which is frequently the case with concussion and mild injury.

The clinical trial will see body fluid samples will be collected from patients ranging from babies to 17-year-olds with suspected mild TBI.

The samples will be studied with respect to a specific biomarker signature following a head injury.

Principal investigator, Dr Sari Malmi, head of the department of paediatric surgery, said that a new test for improving the diagnosis of traumatic brain injury would help to improve the quality of treatments.

Dr. Adrian Harel, CEO of Medicortex, added: “Children in particular will benefit from it since they can be refrained from radiation or sedation which are needed for the CT scan of the head, as well as from an exposure to other sick patients in the hospital.

“Participation of the young patients shortly after a head injury will be a challenge, but we have a committed and skilled clinical team working for us in the hospital.”

Medicortex Finland Oy is a biotechnology company which aims to improve the diagnostics and treatment of TBI.

It has developed technology to capture biomarkers from urine and saliva – which can form the basis of affordable diagnostic tools.

Since the trial was publicised, Finland has announced a state of emergency over the new coronavirus. NR Times has not been able to confirm with Medicortex how this will affect the progress of the trial.